DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors. Ms. Hyveled brings over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence.
“We are thrilled to welcome Liselotte to the TriSalus Board of Directors as we commercialize the TriNav® Infusion System and progress our pipeline through key milestones in 2024 and beyond,” said Mats Wahlstrom, TriSalus Chairman of the Board. “Her wealth of experience and strategic insights will be instrumental in shaping TriSalus' long-term vision of pioneering innovative treatments for liver and pancreatic cancers. We eagerly anticipate Liselotte's contributions to our continued success.”
“Liselotte's extensive background in fostering patient-centric innovations, strategic planning, and the integration of technology and therapeutics will be invaluable assets as we navigate TriSalus’ growth trajectory,” Mary Szela, President and CEO of TriSalus. “Her guidance will be pivotal in our efforts to expand and scale operations while expediting the development of our technology and therapeutic pipelines.”
Ms. Hyveled is a seasoned executive with over two decades of successfully implementing innovative solutions for challenging chronic diseases within a rapidly changing, highly competitive R&D environment. Currently serving as the Chief Patient Officer at Novo Nordisk, she is responsible for ensuring the integration of patient needs and perspectives into the company's decision-making processes and operations, from inception to commercialization. Ms. Hyveled's tenure at Novo Nordisk has been marked by numerous leadership positions and contributions, reflecting her commitment to R&D excellence, breakthrough innovation and advancing patient-centric solutions. She has initiated several social responsibility initiatives at Novo Nordisk with a focus on neurodiversity, disabilities and generational intelligence. Ms. Hyveled holds a Master of Pharmacy Science from Copenhagen University and a Master of Medical Business Strategies from Copenhagen Business School.
Ms. Hyveled commented, “TriSalus has developed a truly groundbreaking platform aimed at addressing the complexities of liver and pancreatic cancers, positioning itself for a pivotal phase of expansion. I am honored to collaborate with the TriSalus board and leadership team to build upon the company's achievements and realize its vision of transforming patient outcomes.”
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors.
The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn.
